New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
13:13 EDTMRVL, QCOR, LRCX, MU, MNK, AAPL, RADEinhorn bought Lam Research shares, sold Rite Aid last quarter
Well-known investor David Einhorn said his hedge fund, Greenlight Capital, had taken a new long position last quarter in Lam Research (LRCX), which develops equipment for semiconductor companies. Also last quarter, Greenlight sold out of its position in Rite Aid (RAD), Einhorn revealed. WHAT'S NEW: Greenlight made a "medium-sized" new investment in Lam Research, Einhorn revealed in his quarterly letter to investors. As the size of transistors shrink, chip makers must run each layer of chips through the manufacturing line multiple times until they work properly, the investor stated. Consequently, the chip makers must buy more of Lam's tools for each manufacturing line, Einhorn explained. The valuations of many high momentum stocks in the tech sector are excessive, but not all tech stocks are too expensive, Einhorn contended. A number of tech stocks - including Apple (AAPL), Lam Research, Marvell Technology (MRVL) and Micron Technology (MU) - "have strong prospects and are undervalued," Einhorn declared. Greenlight holds long positions in all those stocks. Greenlight sold its position in Rite Aid because the company's sales and profits rose, as the hedge fund had expected, and the stock reached fair value, Einhorn explained. WHAT'S NOTABLE: Greenlight continues to be short Questcor (QCOR), which has "a laundry list of problems and risks," the investor said. Among these are ongoing criminal probes and a large number of adverse events, including deaths, experienced by a number of patients who were taking the company's only drug, Acthar, Einhorn wrote. Additionally, a number of insurers have moved towards limiting their reimbursement of the drug, he added. The FDA is examining lab reports which suggest that Questcor's product does not include a highly purified form of Acthar as promoted by the company but a degraded form of the drug, the investor alleged. Mallinckrodt Pharmaceuticals (MNK), which has agreed to buy Questcor, is not properly evaluating the risks of Questcor's drug, Einhorn stated. Mallinckrodt "is setting itself up to be a very attractive short sale candidate if the merger is completed," Einhorn believes. PRICE ACTION: In early afternoon trading, Lam Research lost 1.5% to $69, Rite Aid slid 3.5% to $7, Questcor lost 2% to $95, and Mallinckrodt dropped 3% to $74.50.
News For LRCX;RAD;MNK;QCOR;AAPL;MU;MRVL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
April 23, 2015
13:16 EDTRADPharmacies, PBMs seen as potential buyers after Omnicare said to explore sale
Subscribe for More Information
12:35 EDTAAPLStocks with call strike movement; CSX AAPL
Subscribe for More Information
12:08 EDTRADLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Larsen, along with Mary Ptacek, VP of Pharmaceutical Strategies Group and Ruth Krystopolski, EVP of Sanford Health, discuss the 2016-2017 Pharmacy Benefit Managers selling season and which PBMs are poised to gain share, the impact of WBAs growth plans, recent M&A activity and biosimilars on an Analyst/Industry conference call to be held on April 24 at 2 pm.
11:52 EDTAAPLApple lists several job openings for speech & language teams, Apple Insider says
Subscribe for More Information
11:27 EDTAAPLApple could announce new iPod touch this year, Apple Insider reports
Subscribe for More Information
09:43 EDTAAPLApple not targeting May 8 for Apple Watch second wave launch, 9to5Mac says
Sources told 9to5Mac that Apple is not currently targeting May 8 for its launch of pre-ordering for the Apple Watch in a second wave on countries, refuting a report yesterday from Italy's iSpazio that said that was the date being considered for the next wave of launches. Reference Link
09:35 EDTAAPLActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FB PBR TWTR AA COST TSLA AMZN TXN BAC
07:36 EDTRADUBS estimates Omnicare buyer would need to pay $95 per share
Subscribe for More Information
06:19 EDTAAPLSome Apple Watch orders prepared for shipment ahead of schedule, 9to5Mac says
Though many Apple Watch customers were hit with months-long shipping delays, Apple has started preparing some orders for shipment ahead of schedule, 9to5Mac reports. A spokesperson says "Were happy to be updating many customers today with the news that their Apple Watch will arrive sooner than expected. Our team is working to fill orders as quickly as possible based on the available supply and the order in which they were received." Reference Link
April 22, 2015
18:27 EDTMU, MRVLSemiconductor stocks under pressure after TI, Qualcomm report financial results
Semiconductor stocks are under pressure after earnings reports from Texas Instruments (TXN) and Qualcomm (QCOM). TEXAS INSTRUMENTS: TI reported first quarter results that were lower than analyst expectations, and gave second quarter guidance below consensus estimates. In its Q1 earnings press release, Texas Instruments said its outlook for Q2 is for earnings per share between 60c-70c and revenue in the range of $3.12B-$3.38B. "Our estimates assume continuing weakness in our communications equipment and personal electronics markets, particularly for wireless infrastructure equipment and PCs, respectively. We also do not expect a near-term rebound in foreign currency exchange rates. The annual effective tax rate for 2015 is expected to be about 30%." QUALCOMM: Qualcomm reported Q2 results that were better than analyst's average estimates, but lowered its fiscal year 2015 EPS and revenue views. Qualcomm CEO Steve Mollenkopf said, "While we remain confident in the significant growth opportunities ahead, we are reducing our QCT outlook for fiscal 2015, primarily due to the increased impact of customer share shifts within the premium tier and a decline in our share at a large customer." PRICE ACTION: In after-hours trading, shares of Texas Instruments are down over 6%, while Qualcomm shares are down almost 3%. Other publicly traded companies in the space include AMD (AMD), Intel (INTC), Marvell (MRVL), Microchip (MCHP), Micron (MU), NVIDIA (NVDA), Altera (ALTR), Xilinx (XLNX), and Maxim Integrated (MXIM).
17:23 EDTAAPLNokia approaches Apple, Amazon, Facebook in sale of maps unit, Bloomberg says
Subscribe for More Information
16:00 EDTAAPLOptions Update; April 22, 2015
iPath S&P 500 VIX Short-Term Futures down 22c to 21.30. Option volume leaders: AAPL TSLA TWTR MCD FB PBR AMZN KMI MYL C according to Track Data.
15:12 EDTAAPLAOL debuts three apps for Apple Watch
AOL (AOL) announced the debut of three apps built for the Apple Watch, including Pip, the newly redesigned The Huffington Post app, and the AOL app. Each of them will be available on April 24, the company stated.
14:47 EDTMRVLEarnings Watch: Texas Instruments reports amid M&A focus in semiconductor space
Texas Instruments (TXN) is expected to report first quarter earnings after the close on Wednesday, April 22, with a conference call scheduled for 5:30 pm ET. Texas Instruments is a global semiconductor manufacturer operating in four segments: Analog, Embedded Processing, Wireless and Other. EXPECTATIONS: Analysts are looking for earnings per share of 62c on revenue of $3.2B. The consensus range is 61c-64c for EPS on revenue of $3.18B-$3.21B, according to First Call. On its last earning call, Texas Instruments said it expected Q1 EPS of 57c-67c and revenue of $3.07B-$3.33B. LAST QUARTER: On January 26, Texas Instruments reported adjusted fourth quarter EPS of 69c, which matched consensus expectations at that time. Its Q4 revenue of $3.27B came in just above the consensus forecast of $3.26B. Texas Instruments said its inventory ended the quarter at 117 days and noted on its associated conference call that it believe inventories were at "healthy levels." Texas Instruments also said then that it expected its embedded operating margins to increase. STREET RESEARCH: The day after TI's last quarterly report, Ascendiant raised its price target for Texas Instruments shares to $64 from $56 and reiterated a Buy rating on the stock. The firm attributed the post-earnings slide the stock experienced then to profit taking, rather than a fundamental disappointment. That same week, Argus increased its price target on Texas Instruments to $62 from $54 and said it expected the company's operating trends to continue to strengthen. Argus kept a Buy rating on the shares. Acquiring companies in the semiconductor space "can materially outperform the market," Jefferies analyst Mark Lipacis wrote in a note to investors on March 9. At that time, Lipacis identified Texas Instruments, NXP Semiconductors (NXPI), Avago (AVGO), Marvell (MRVL), Maxim Integrated (MXIM), Broadcom (BRCM), Altera (ALTR), and Xilinx (XLNX) as companies that were well-positioned to make acquisitions in the future. WHAT'S NOTABLE: On March 1, NXP Semiconductors and Freescale Semiconductor (FSL) announced that they have entered into a definitive agreement under which NXP will merge with Freescale in a transaction valuing the combined enterprise at just over $40B. Recent media reports suggested that Intel's (INTC) talks to acquire Altera stalled when the latter wanted more than Intel was willing to pay. PRICE ACTION: Since the day after last quarter's report, Texas Instruments' stock has rallied nearly 7%. In afternoon trading, Texas Instruments gained over 1% to $58.76.
10:31 EDTAAPLUBS U.S. IT Hardware analyst holds an analyst/industry conference call
Subscribe for More Information
09:54 EDTAAPLApple Watch pre-orders may start May 8 in next wave of countries, MacRumors says
Subscribe for More Information
08:00 EDTRADRite Aid weakness a buying opportunity, says Cowen
Cowen said to add to Rite aid positions on the recent pullback as the reason for the weakness is the receding of a takeout premium, which was not in the firm's investment thesis to begin with. The firm sees strong underlying fundamentals and strong returns from its store remodeling program, which is still in its early innings. Cowen reiterated its Outperform rating and $12 price target on Rite Aid shares.
07:20 EDTAAPLApple survey continues to show strong iPhone demand, says UBS
Subscribe for More Information
07:08 EDTAAPLPriceline Apple launches Apple Watch travel applications
Subscribe for More Information
06:16 EDTAAPLApple retail chief discusses Apple Watch, MacBook in video, BI reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use